Riskpilot← Back to searchSign inGet full accessHerantis Pharma Oyj
OYJActiveY-tunnus 2198665-7Bertel Jungin Aukio 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20081 employees
Revenue 2024
EUR 0
EBITDA margin
—
-3356% vs 2023
Equity ratio
-9.4%
Financial strength
Net profit 2024
EUR -4,9M
-1865% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR -5M | -3356% |
| Net profit | EUR -4,9M | -1865% |
| Total assets | EUR 2,6M | -100% |
| Equity | EUR -243K | -100% |
| Employees | 1 | — |
Legal name
Herantis Pharma Oyj
Y-tunnus number
2198665-7
Legal form
Julkinen osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26. toukokuuta 2008
Share capital
EUR 80 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on bioteknologiaan ja lääketieteeseen liittyvä tutkimus- ja tuotekehitystoiminta sekä bioteknologiaan ja lääketieteeseen liittyvien tuotteiden ja palvelujen tuotanto, myynti ja markkinointi Suomessa ja ulkomailla. Yhtiö voi omistaa ja hallinnoida kiinteistöjä ja arvopapereita sekä käydä niillä kauppaa. Yhtiö voi harjoittaa toimintaansa suoraan taikka tytär- tai osakkuusyhtiöidensä välityksellä.
Address
Bertel Jungin Aukio 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 5 307 | 0 |
| Staff expenses | −2 035 | −2 246 | −2 649 | −173 516 | −1 488 |
| EBITDA | −5 830 | −8 890 | −7 833 | 154 | −5 026 |
| Depreciation & amort. | −160 | −160 | −160 | −0 | −0 |
| EBIT | −5 990 | −9 050 | −7 993 | 15 437 | −5 026 |
| Net financials | −1 057 | −14 526 | −1 331 | 125 | 87 |
| Profit before tax | −7 047 | −23 576 | −9 324 | 280 | −4 883 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 047 | −23 576 | −9 324 | 280 | −4 939 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 26 311 | 6 918 | 6 232 | 674 564 | 2 571 |
| Equity | 20 091 | 554 | −60 | 472 635 | −243 |
| Long-term debt | 3 666 | 4 469 | 4 391 | 2 985 | 2 180 |
| Short-term debt | 2 553 | 1 895 | 1 902 | 198 944 | 634 |
| Total debt | 6 220 | 6 364 | 6 292 | 201 929 | 2 814 |
EBITDA margin
-502648900.0%
This company
15.8%
Market median
-3181322252% vs market
20202024
Equity ratio
-9.4%
This company
38.2%
Market median
-125% vs market
20202024
Return on equity
-493926700.0%
This company
18.4%
Market median
-2684384339% vs market
20202024
Net profit margin
-493926700.0%
This company
8.1%
Market median
-6097860594% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
11.59×
This company
0.62×
Market median
-1769% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AT Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (4) | ||
CR Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
PI Chief Executive Officer | Chief Executive Officer | 2014 – 2020 |
MA | Audit | 2008 – 2021 |
PV | Audit | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairperson | 2020 | |
| Board of Directors | 2015 | |
| Board of Directors | 2015 | |
| Board of Directors | 2021 | |
| Board of Directors | 2020 | |
| Former (3) | ||
| Board of Directors | 2019 – 2020 | |
| Board of Directors | 2015 – 2023 | |
| Chairperson | 2015 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Herantis Pharma Oyj also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Craig Richard Cook | Chief Executive Officer | 0 companies |
| Pekka Ilmari Simula | Chief Executive Officer | 0 companies |
| Antti Tapani Vuolanto | Chief Executive Officer | 0 companies |
| Martin Andreas Grandell | Audit | 0 companies |
| Panu Veijo Ilmari Vänskä | Audit | 0 companies |
| Ingrid Atteryd Heiman | Board of Directors | 0 companies |
| Timo Ilari Veromaa | Chairperson | 0 companies |
| Frans Gustaf Wuite | Board of Directors | 0 companies |
| James Neil Phillips | Board of Directors | 0 companies |
| Aki Pellervo Prihti | Board of Directors | 0 companies |
| Hilde Furberg | Board of Directors | 0 companies |
| Mats Johan Peter Thorén | Board of Directors | 0 companies |
| Pekka Allan Antero Mattila | Chairperson | 0 companies |